A Phase I Trial of the Dual Farnesyltransferase and Geranylgeranyltransferase Inhibitor L-778,123 and Radiotherapy for Locally Advanced Pancreatic Cancer
Authors:
Open Access
- 15 August 2004
- journal article
- clinical trial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (16) , 5447-5454
Abstract
Purpose: Preclinical and clinical studies have demonstrated that inhibition of prenylation can radiosensitize cell lines with activation of Ras and produce clinical response in patients with cancer. The aim of this study was to determine the maximally tolerated dose of the dual farnesyltransferase and geranylgeranyltransferase I inhibitor L-778,123 in combination with radiotherapy for patients with locally advanced pancreatic cancer. Experimental Design: L-778,123 was given by continuous intravenous infusion with concomitant radiotherapy to 59.4 Gy in standard fractions. Two L-778,123 dose levels were tested: 280 mg/m2/day over weeks 1, 2, 4, and 5 for dose level 1; and 560 mg/m2/day over weeks 1, 2, 4, 5, and 7 for dose level 2. Results: There were no dose-limiting toxicities observed in the eight patients treated on dose level 1. Two of the four patients on dose level 2 experienced dose-limiting toxicities consisting of grade 3 diarrhea in one case and grade 3 gastrointestinal hemorrhage associated with grade 3 thrombocytopenia and neutropenia in the other case. Other common toxicities were mild neutropenia, dehydration, hyperglycemia, and nausea/vomiting. One patient on dose level 1 showed a partial response of 6 months in duration. Both reversible inhibition of HDJ2 farnesylation and radiosensitization of a study patient-derived cell line were demonstrated in the presence of L-778,123. K-RAS mutations were found in three of the four patients evaluated. Conclusions: The combination of L-778,123 and radiotherapy at dose level 1 showed acceptable toxicity in patients with locally advanced pancreatic cancer. Radiosensitization of a patient-derived pancreatic cancer cell line was observed.Keywords
This publication has 35 references indexed in Scilit:
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Farnesyl transferase inhibitor SCH66336 is cytostatic, pro‐apoptotic and enhances chemosensitivity to cisplatin in melanoma cellsInternational Journal of Cancer, 2003
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- Future directions in the treatment of pancreatic cancerSeminars in Oncology, 2002
- Inhibition of human tumor cell growthin vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228International Journal of Cancer, 2001
- HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB PathwayJournal of Biological Chemistry, 2000
- Non-Ras targets of farnesyltransferase inhibitors: focus on RhoOncogene, 1998
- High frequency of Ki‐ras codon 12 mutations in pancreatic adenocarcinomasInternational Journal of Cancer, 1989
- Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genesCell, 1988